Cargando…

Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines

Although atorvastatin (ATV) is well-tolerated, patients may report muscle complaints. These are difficult to predict owing to high interindividual variability. Such side effects are linked to intramuscular accumulation of ATV. This study aimed to investigate the relative role of transporters express...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoste, Emilia, Paquot, Adrien, Panin, Nadtha, Horion, Shaleena, El Hamdaoui, Halima, Muccioli, Giulio G., Haufroid, Vincent, Elens, Laure
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168106/
https://www.ncbi.nlm.nih.gov/pubmed/36253893
http://dx.doi.org/10.1097/FTD.0000000000001043
_version_ 1785038803501580288
author Hoste, Emilia
Paquot, Adrien
Panin, Nadtha
Horion, Shaleena
El Hamdaoui, Halima
Muccioli, Giulio G.
Haufroid, Vincent
Elens, Laure
author_facet Hoste, Emilia
Paquot, Adrien
Panin, Nadtha
Horion, Shaleena
El Hamdaoui, Halima
Muccioli, Giulio G.
Haufroid, Vincent
Elens, Laure
author_sort Hoste, Emilia
collection PubMed
description Although atorvastatin (ATV) is well-tolerated, patients may report muscle complaints. These are difficult to predict owing to high interindividual variability. Such side effects are linked to intramuscular accumulation of ATV. This study aimed to investigate the relative role of transporters expressed in muscle tissue in promoting or limiting drug access to cells. The impact of common single nucleotide polymorphisms (SNPs) in SLCO2B1 coding for OATP2B1 and ABCC1 coding for MRP1 on ATV transport was also evaluated. METHODS: HEK293 cells were stably transfected with plasmids containing cDNA encoding wild-type or variant SLCO2B1 and/or ABCC1 to generate single and double stable transfectant HEK293 recombinant models overexpressing variant or wild-type OATP2B1 (influx) and/or MRP1 (efflux) proteins. Variant plasmids were generated by site-directed mutagenesis. Expression analyses were performed to validate recombinant models. Accumulation and efflux experiments were performed at different concentrations. ATV was quantified by LC-MS/MS, and kinetic parameters were compared between single and double HEK transfectants expressing wild-type and variant proteins. RESULTS: The results confirm the involvement of OATP2B1 and MRP1 in ATV cellular transport because it was demonstrated that intracellular accumulation of ATV was boosted by OATP2B1 overexpression, whereas ATV accumulation was decreased by MRP1 overexpression. In double transfectants, it was observed that increased ATV intracellular accumulation driven by OATP2B1 influx was partially counteracted by MRP1 efflux. The c.935G > A SNP in SLCO2B1 was associated with decreased ATV OATP2B1-mediated influx, whereas the c.2012G > T SNP in ABCC1 seemed to increase MRP1 efflux activity against ATV. CONCLUSIONS: Intracellular ATV accumulation is regulated by OATP2B1 and MRP1 transporters, whose functionality is modulated by natural genetic variants. This is significant because it may play a role in ATV muscle side-effect susceptibility.
format Online
Article
Text
id pubmed-10168106
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-101681062023-05-10 Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines Hoste, Emilia Paquot, Adrien Panin, Nadtha Horion, Shaleena El Hamdaoui, Halima Muccioli, Giulio G. Haufroid, Vincent Elens, Laure Ther Drug Monit Original Article Although atorvastatin (ATV) is well-tolerated, patients may report muscle complaints. These are difficult to predict owing to high interindividual variability. Such side effects are linked to intramuscular accumulation of ATV. This study aimed to investigate the relative role of transporters expressed in muscle tissue in promoting or limiting drug access to cells. The impact of common single nucleotide polymorphisms (SNPs) in SLCO2B1 coding for OATP2B1 and ABCC1 coding for MRP1 on ATV transport was also evaluated. METHODS: HEK293 cells were stably transfected with plasmids containing cDNA encoding wild-type or variant SLCO2B1 and/or ABCC1 to generate single and double stable transfectant HEK293 recombinant models overexpressing variant or wild-type OATP2B1 (influx) and/or MRP1 (efflux) proteins. Variant plasmids were generated by site-directed mutagenesis. Expression analyses were performed to validate recombinant models. Accumulation and efflux experiments were performed at different concentrations. ATV was quantified by LC-MS/MS, and kinetic parameters were compared between single and double HEK transfectants expressing wild-type and variant proteins. RESULTS: The results confirm the involvement of OATP2B1 and MRP1 in ATV cellular transport because it was demonstrated that intracellular accumulation of ATV was boosted by OATP2B1 overexpression, whereas ATV accumulation was decreased by MRP1 overexpression. In double transfectants, it was observed that increased ATV intracellular accumulation driven by OATP2B1 influx was partially counteracted by MRP1 efflux. The c.935G > A SNP in SLCO2B1 was associated with decreased ATV OATP2B1-mediated influx, whereas the c.2012G > T SNP in ABCC1 seemed to increase MRP1 efflux activity against ATV. CONCLUSIONS: Intracellular ATV accumulation is regulated by OATP2B1 and MRP1 transporters, whose functionality is modulated by natural genetic variants. This is significant because it may play a role in ATV muscle side-effect susceptibility. Therapeutic Drug Monitoring 2023-06 2023-05-08 /pmc/articles/PMC10168106/ /pubmed/36253893 http://dx.doi.org/10.1097/FTD.0000000000001043 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Article
Hoste, Emilia
Paquot, Adrien
Panin, Nadtha
Horion, Shaleena
El Hamdaoui, Halima
Muccioli, Giulio G.
Haufroid, Vincent
Elens, Laure
Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title_full Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title_fullStr Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title_full_unstemmed Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title_short Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
title_sort genetic polymorphisms in slco2b1 and abcc1 conjointly modulate atorvastatin intracellular accumulation in hek293 recombinant cell lines
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168106/
https://www.ncbi.nlm.nih.gov/pubmed/36253893
http://dx.doi.org/10.1097/FTD.0000000000001043
work_keys_str_mv AT hosteemilia geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT paquotadrien geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT paninnadtha geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT horionshaleena geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT elhamdaouihalima geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT muccioligiuliog geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT haufroidvincent geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines
AT elenslaure geneticpolymorphismsinslco2b1andabcc1conjointlymodulateatorvastatinintracellularaccumulationinhek293recombinantcelllines